MetaVia (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, has announced it has secured $9.0 million in new investment capital. This funding round will support the company's ongoing efforts to advance its pipeline of therapeutic candidates, including DA-1726 for the treatment of obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
MetaVia's lead candidate, DA-1726, is a novel, dual oxyntomodulin (OXM) analog agonist designed for once-a-week injection. It functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist, aiming to decrease food intake while increasing energy expenditure. The company is also developing DA-1241, a novel G-protein-coupled receptor 119 (GPR119) agonist. Pre-clinical studies for DA-1241 have indicated positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, showing potential to reduce hepatic steatosis, hepatic inflammation, and liver fibrosis.
The $9.0 million in capital is expected to support the continued clinical development of these programs and general corporate operations as MetaVia progresses its therapeutic candidates through various stages. Dong-A ST Co. Ltd., a strategic partner and the largest investor, continues its support for MetaVia. Dong-A ST, part of the Dong-A Socio Group based in South Korea, provides MetaVia with access to its Research Center's R&D, scientific, and CMC expertise, reinforcing the company's development capabilities.
This investment underscores confidence in MetaVia's approach to addressing significant unmet medical needs in cardiometabolic health. The company plans to leverage these funds to accelerate its clinical development milestones and expand its research initiatives, aiming to bring innovative treatments to patients suffering from obesity and MASH.
.png&w=3840&q=75)
